When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent?

When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent?

When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Peter Nash, MD

Peter Nash, MD

Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia